Shanghai INT Medical Instruments Co., Ltd. (HKG:1501)
32.40
+0.14 (0.43%)
Jan 21, 2026, 3:08 PM HKT
HKG:1501 Revenue
Shanghai INT Medical Instruments had revenue of 461.08M CNY in the half year ending June 30, 2025, with 35.70% growth. This brings the company's revenue in the last twelve months to 920.71M, up 14.32% year-over-year. In the year 2024, Shanghai INT Medical Instruments had annual revenue of 851.95M with 13.17% growth.
Revenue (ttm)
920.71M CNY
Revenue Growth
+14.32%
P/S Ratio
5.60
Revenue / Employee
530.67K CNY
Employees
1,735
Market Cap
5.65B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 851.95M | 99.12M | 13.17% |
| Dec 31, 2023 | 752.84M | 166.95M | 28.50% |
| Dec 31, 2022 | 585.88M | 121.21M | 26.08% |
| Dec 31, 2021 | 464.68M | 106.25M | 29.64% |
| Dec 31, 2020 | 358.43M | 71.97M | 25.12% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 38.69B |
| Alibaba Health Information Technology | 36.09B |
| Sino Biopharmaceutical | 33.49B |
| CSPC Pharmaceutical Group | 28.65B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |